Prognosis
Moderna Seeks U.S. Clearance of Covid Shot for Young Kids
- Pressure mounting on regulators to give toddlers protection
- Two doses of vaccine shown providing strong immune response
This article is for subscribers only.
Moderna Inc. applied for emergency use authorization for its Covid-19 vaccine in children from six months to under 6 years old after a successful trial showed two doses generate high levels of antibodies to the virus.
The highly anticipated application comes just over a month after Moderna said a large trial showed two low doses of its vaccine produced powerful immune responses in young kids. Even though its effectiveness against omicron-related infections is modest, the application will put tremendous pressure on the Food and Drug Administration to quickly make a decision on whether to authorize it.